MeSH tree: D12.776.124.486.485.114.224.060.750
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect ...
Mar 13, 2026
0
9
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.
Jun 10, 2025
0
18
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer ...
Jun 1, 2025
0
30
Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) ...
Jan 27, 2025
0
15
Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.
Nov 22, 2024
0
26
The 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a study presented at the American Society of Clinical ...
Oct 2, 2024
0
21
Macquarie University researchers have discovered new information about how oral cancer cells may block the body's immune response. This could lead to better treatments for this aggressive disease.
Sep 17, 2024
0
29
A multi-disciplinary task force convened by the American Society for Radiation Oncology has issued new guidelines for radiation therapy for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).
Jun 18, 2024
0
41
Scientists have used breast cancer cells' weakness against themselves by linking a tumor-selective antibody with a cell-killing drug to destroy hard-to-treat tumors.
May 22, 2024
0
52
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results ...
Apr 8, 2024
0
27
